Cargando…

Low-Molecular-Weight Heparin Use in a Case of Noncardiogenic Multifocal Perinatal Thromboembolic Stroke

A full-term neonate suffered multifocal cerebral infarctions due to multiple large vessel thrombi. Thrombophilia and cardiovascular assessments were negative, but due to the severity of the lesions and the concern for expansion of the thrombi or future embolic events, treatment with low-molecular-we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saxonhouse, Matthew A., Tarquinio, Dan, Carney, Paul R., Bennett, Jeff, Smith, Amy, Hunger, Stephen P., Geyer, James D.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2009
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778868/ https://www.ncbi.nlm.nih.gov/pubmed/19946420 http://dx.doi.org/10.1155/2009/153643

Ejemplares similares

Pulmonary edema − cardiogenic or noncardiogenic?
por: Sureka, Binit, et al.
Publicado: (2015)

Phosphodiesterase 4D Gene and Risk of Noncardiogenic Ischemic Stroke in a Korean Population
por: Kim, Myeong-Kyu, et al.
Publicado: (2009)

A Case of Noncardiogenic Pulmonary Edema by Ethanolamine Oleate
por: Lee, Jee Yun, et al.
Publicado: (1994)

The Double-Edged Sword: Naloxone-Induced Noncardiogenic Pulmonary Edema
por: Marsalisi, Christopher, et al.
Publicado: (2023)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Severe noncardiogenic pulmonary edema after cardiopulmonary bypass: Case report
por: Zeng, Jianfeng, et al.
Publicado: (2023)

In-hospital prognosis of first-ever noncardiogenic ischemic stroke in patients with and without indication for prestroke antiplatelet therapy: Chinese Stroke Center Alliance
por: Xu, Yu-Yuan, et al.
Publicado: (2021)

Noncardiogenic Pulmonary Edema after Amlodipine Overdose without Refractory Hypotension and Bradycardia
por: Hedaiaty, M., et al.
Publicado: (2015)

Noninvasive ventilation in a patient with noncardiogenic pulmonary edema following amlodipine poisoning
por: Shetty, Kishan, et al.
Publicado: (2015)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022)

Successful treatment of refractory hypotension, noncardiogenic pulmonary edema and acute kidney injury after an overdose of amlodipine
por: Kute, Vivek B., et al.
Publicado: (2011)

Severe Noncardiogenic Pulmonary Edema Secondary to Massive Verapamil Overdose and Treatment with Venovenous Extracorporeal Membrane Oxygenation
por: Ho, An, et al.
Publicado: (2020)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Heparin: Multifocal intracerebral haemorrhage and subarachnoid haemorrhage: case report
Publicado: (2021)

Fatal noncardiogenic pulmonary edema related to nonionic, iso-osmolar iodine contrast medium: one case report
por: Yi, Kun-ming, et al.
Publicado: (2022)

An Internist’s Approach to a Case of Negative Pressure Pulmonary Edema: A Rare Cause of Noncardiogenic Pulmonary Edema
por: Cerna-Viacava, Renato, et al.
Publicado: (2023)

Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
por: Smrke, Alannah, et al.
Publicado: (2017)

Efficacy of Low Molecular Weight Heparin in Preventing Perinatal Venous Thrombosis: A Meta-Analysis
por: Huang, Yan, et al.
Publicado: (2022)

Acute noncardiogenic pulmonary edema after neostigmine administration during the recovery period of general anesthesia: A case report
por: Zhang, Wenjing, et al.
Publicado: (2018)

Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
por: Prandoni, Paolo
Publicado: (2008)

The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy
por: Zou, Peimei, et al.
Publicado: (2019)

Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence
por: Christopoulou, Athina, et al.
Publicado: (2022)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
por: Pineo, Graham F, et al.
Publicado: (2012)

Safety of heparin prophylaxis for venous thromboembolism in patients with neurotrauma
por: Puri, G, et al.
Publicado: (2010)

The Efficacy of Low Molecular Weight Heparin for the Prevention of Venous Thromboembolism after Hip Fracture Surgery in Korean Patients
por: Kim, Kwang-Kyoun, et al.
Publicado: (2016)

Predictive value of serum initial brain natriuretic peptide and troponin on functional prognosis in noncardiogenic patients with anterior and posterior circulation cerebral infarction
por: Lu, Wan-Ting, et al.
Publicado: (2022)

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism
por: Smythe, Maureen A., et al.
Publicado: (2016)

Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia
por: Costanzo, Luca, et al.
Publicado: (2020)

Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism
por: Recio-Boiles, Alejandro, et al.
Publicado: (2019)

Effect of hydrocolloid dressing combined with low molecular weight heparin and calcium on scar hyperplasia in burn patients with venous thromboembolism
por: Li, Chengzhi, et al.
Publicado: (2023)

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes
por: Spyropoulos, Alex C, et al.
Publicado: (2008)

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
por: Bamber, Luke, et al.
Publicado: (2015)

Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
por: Lanitis, Tereza, et al.
Publicado: (2017)

Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)
por: Otero, Remedios, et al.
Publicado: (2022)

Comparative Efficacy of Oral Apixaban and Subcutaneous Low Molecular Weight Heparins in the Treatment of Cancer-Associated Thromboembolism: A Meta-Analysis
por: Baloch, Maryam F, et al.
Publicado: (2023)

Heparin/low molecular weight heparins: Thrombocytopenia: 7 case reports
Publicado: (2021)

A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making
por: Johnston, Amy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_crtg9for09ekgg6rg40nig7q00